EUVIMEDEUVIMED entdecken
Crossref

Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia

Haoting Chen, Dongyao Wang, Yuying Yao, Yafang Xiao, Zhuangzhuang Zhao, Ziqi Zhang, Shaoyu Liu, Xinlu Wang, Shiying Yang, Panpan Huang, Zijian Zhou, Xiaoyu Zhu und 1 weitere

Advanced Functional Materials · 2024-11 · 34 (48)

DOI: 10.1002/adfm.202411439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 15.09.2024. Verfasst von Haoting Chen und 12 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) with anti‐CD47 antibodies (aCD47) is a promising therapeutic approach that has the potential to revolutionize the treatment of acute myeloid leukemia (AML). However, the low immune response rate and high systemic hematotoxicity remain substantial barriers to its success in clinical AML treatment. A synthetic protein nanogel formulation of aCD47 and resiquimod (R848) (termed CR‐TNG) is developed that targets TIM‐3 on the surface of leukemia cells. Upon intravenous injection, the CR‐TNG efficiently conjugates onto the blood‐circulating leukemia cells and migrates toward the bone marrow (BM) by exploiting the natural BM homing capability of leukemia cells. CR‐TNG releases aCD47 and R848 in a bone marrow hypoxic microenvironment, which significantly induces immunosuppression and enhances the anti‐leukemia immune response by activating macrophage “eat me” signaling and priming myeloid macrophages in the BM niche. These findings provide a leukemia cell‐hitchhiking drug delivery strategy that addresses both systemic hematotoxicity and low immune response rate in AML.

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Chen, H., Wang, D., Yao, Y., Xiao, Y., Zhao, Z., Zhang, Z., Liu, S., Wang, X., Yang, S., Huang, P., Zhou, Z., Zhu, X., & Guo, W. (2024). Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia. Advanced Functional Materials, 34(48). https://doi.org/10.1002/adfm.202411439

Vancouver

Chen H, Wang D, Yao Y, Xiao Y, Zhao Z, Zhang Z, et al. Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia. Advanced Functional Materials. 2024;34(48). doi:10.1002/adfm.202411439

BibTeX
@article{Chen2024,
  author = {Chen, Haoting and Wang, Dongyao and Yao, Yuying and Xiao, Yafang and Zhao, Zhuangzhuang and Zhang, Ziqi and Liu, Shaoyu and Wang, Xinlu and Yang, Shiying and Huang, Panpan and Zhou, Zijian and Zhu, Xiaoyu and Guo, Weisheng},
  title = {Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia},
  journal = {Advanced Functional Materials},
  year = {2024},
  volume = {34},
  number = {48},
  doi = {10.1002/adfm.202411439}
}
Kostenlos starten →